Hadassah University Medical Center has been chosen to participate in a multicenter clinical trial of the Aposense Ltd.’s EarliTest diagnostic system for detection of brain, lung, and cervical cancer.

Aposense is a clinical stage molecular imaging and drug development company and the EarliTest system is a molecular imaging and diagnostic tool that helps assess a tumor’s response to cancer treatment. Hadassah joins 10 other prestigious medical institutions in this Phase II clinical trial, including New York’s Memorial Sloan-Kettering Cancer Center, Harvard Medical School (MA), and the University of Pennsylvania Medical Center.